ABSTRACT

Chronic obstructive pulmonary disease (COPD) patient care must include confirming a diagnosis with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that airflow obstruction assessed by spirometry only partially reflects disease severity, a thorough clinical evaluation of the patient should include assessment of symptom burden and risk of exacerbations that permits the implementation of evidence-informed pharmacological and nonpharmacological interventions. This guideline provides recommendations from a comprehensive systematic review with a meta-analysis and expert-informed clinical remarks to optimize maintenance pharmacological therapy for individuals with stable COPD, and a revised and practical treatment pathway based on new evidence since the 2019 update of the Canadian Thoracic Society (CTS) Guideline. The key clinical questions were developed using the Patients/Population (P), intervention(s) (I), Comparison/Comparator (C), and Outcome (O) model for 3 questions that focuses on the outcomes of symptoms (dyspnea)/health status, acute exacerbations and mortality. The evidence from this systematic review and meta-analysis leads to the recommendation that all symptomatic patients with spirometry-confirmed COPD should receive long-acting bronchodilator maintenance therapy. Those with moderate to severe dyspnea (modified Medical Research Council ≥2) and/or impaired health status (COPD Assessment Test ≥10) and a low risk of exacerbations should receive combination therapy with a long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA). For those with a moderate/severe dyspnea and/or impaired health status and a high risk of exacerbations should be prescribed triple combination therapy (LAMA/LABA/ICS) azithromycin, roflumilast or N-Acetylcysteine is recommended for specific populations; a recommendation against the use of theophylline, maintenance systemic oral corticosteroids such as prednisone and mono-ICS is made for all COPD patients.

RÉSUMÉ

Les soins aux patients atteints de maladie pulmonaire obstructive chronique (MPOC) doivent inclure la confirmation d’un diagnostic par spirométrie post-bronchodilatateur. En raison de l’hétérogénéité clinique et du fait que l’obstruction du flux d’air évaluée par spirométrie ne reflète que partiellement la gravité de la maladie, une évaluation clinique approfondie du patient doit inclure une évaluation des symptômes et du risque d’exacerbations permettant la mise en œuvre d’interventions pharmacologiques et non pharmacologiques fondées sur des données probantes. Cette ligne directrice formule des recommandations issues d’une revue systématique complète, assortie d’une méta-analyse et d’observations cliniques d’experts, afin d’optimiser le traitement pharmacologique d’entretien pour les personnes atteintes de MPOC stable, de même qu’un parcours de soins révisé et pratique fondé sur de nouvelles données probantes depuis la mise à jour de la Ligne directrice de la Société canadienne de thoracologie (SCT) de 2019. Les questions cliniques clés ont été élaborées à l’aide du modèle Patients/Population (P), Intervention(s) (I), Comparaison/Comparateur (C) et Résultat (O) pour trois questions portant sur les résultats des symptômes (dyspnée)/état de santé, les exacerbations aiguës et la mortalité. Les données probantes de cette revue systématique et de cette méta-analyse conduisent à recommander que tous les patients symptomatiques atteints

CONTACT Jean Bourbeau jean.bourbeau@mcgill.ca Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve West, office 3D.62, Montréal QC H4A 3S5 Canada.

© 2023 Canadian Thoracic Society and American College of Chest Physicians. Published by Taylor & Francis, LLC and Elsevier Inc. All rights reserved.
Introduction

Chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD), lead to a high burden of disease reflected in morbidity, mortality and health care costs. COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. In 2019, it was associated with 4.7% of global disability-adjusted life years (DALYs) and ranked as the sixth leading cause of DALYs. In Canada, all-cause mortality rates were higher among those living with COPD than those without COPD, across all age groups; rate ratios ranged from 3.7 in the 50-54 age group to 1.7 in the 85 and older age group. COPD accounts for over 50% of chronic respiratory disease prevalence among males and females, and for an astounding 81.7% of the total number of deaths from chronic respiratory diseases.

The course of COPD over time is characterized by persistent dyspnea and disability with acute exacerbations that lead to a faster lung function decline, worsened health status, and increased hospitalizations. Exacerbations are the main driver of healthcare costs and the large economic burden in COPD has been documented in a number of studies. The 30-day readmission rate for acute exacerbations in different developed countries can be as high as 22%, and poor discharge medication reconciliation is among the factors thought to contribute to early readmissions. Severe exacerbations are also associated with increased all-cause mortality.

There is an urgent need to offer effective and personalized management plans for individuals living with COPD to improve symptoms and health status, prevent acute exacerbations and reduce mortality. An integrative comprehensive approach to COPD management that includes confirming a diagnosis of COPD with spirometry, evaluating symptom burden, health status and risk of exacerbations over time and implementing pharmacological and nonpharmacological treatments is both effective and recommended. Importantly, relevant and evidence-based nonpharmacologic interventions such as smoking cessation counseling, vaccinations, self-management education, and pulmonary rehabilitation aimed at healthy lifestyle behaviors and improved daily management of COPD are vital for effective comprehensive management of COPD.

This clinical practice guideline, informed by a comprehensive systematic review and a meta-analysis: (i) provides an update from the Canadian Thoracic Society (CTS) Clinical Practice Guideline on Pharmacotherapy in Patients with COPD – 2019 for the optimal approach to the pharmacological treatment of individuals with COPD to alleviate symptoms, improve health status and prevent exacerbations, and (ii) synthesizes emerging evidence on whether maintenance pharmacotherapy reduces mortality. This guideline has systematically evaluated evidence and formulated corresponding evidence-based recommendations for each key clinical question and outlines a practical clinical treatment pathway based on those recommendations, the quality and strength of the evidence, balance of benefits and harms and perceived patient preferences.

This guideline does not address nonpharmacological interventions (e.g., smoking cessation counseling, vaccines, self-management education, pulmonary rehabilitation), long term oxygen therapy, noninvasive ventilation, interventional bronchoscopy or surgery, respiratory palliative care or management of acute exacerbations.

Objectives

The overall objective of this CTS guideline is to help clinicians match pharmacological treatment to the clinical status of individuals with stable COPD. This is an important step toward personalizing therapy based on individual characterization.

The specific objective is to provide clinical guidance with evidence-based recommendations from a systematic review with a meta-analysis and expert-informed clinical remarks to optimize maintenance pharmacological therapy aimed at alleviating dyspnea and improving health status, preventing exacerbations and reducing mortality for individuals with stable COPD.

Target patient population

The update applies to all individuals with stable COPD.

Target users

<table>
<thead>
<tr>
<th>Health Care Providers</th>
<th>Nonhealth Care Providers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certified Respiratory Educators</td>
<td>Healthcare decision-makers (i.e., national, provincial and local policy makers)</td>
</tr>
<tr>
<td>Internists</td>
<td>Patient advocates</td>
</tr>
<tr>
<td>Nurse Practitioners/Physician Assistants</td>
<td>Patients</td>
</tr>
<tr>
<td>Pharmacists</td>
<td>Healthcare researchers</td>
</tr>
<tr>
<td>Primary Care Physicians</td>
<td>Knowledge translation specialists</td>
</tr>
<tr>
<td>Respirologists</td>
<td></td>
</tr>
</tbody>
</table>

Visions to the integrated and comprehensive management of COPD

Figure 1 shows the approach to integrated and comprehensive management in COPD. Integrated and comprehensive clinical care should include: (i) diagnosis of COPD confirmed with...
**Goals of Therapy**
- Alleviate Dyspnea
- Improve Health Status
- Prevent AECOPD
- Reduce Mortality

---

**Figure 1. Integrated Comprehensive Management of COPD**
Integrated comprehensive management of COPD includes confirming COPD diagnosis with postbronchodilator spirometry, evaluation and on-going monitoring of dyspnea/symptom burden and risk of exacerbations and use of both pharmacologic and nonpharmacologic interventions (see Figure 3) to alleviate dyspnea/symptoms, improve health status, prevent AECOPD and reduce mortality. The approach should not be viewed as “stepwise” and may not necessarily occur in the order they appear for all patients. Self-Management Education includes optimizing inhaler device technique and [re]-review, assessment and review of medication adherence, breathing and cough techniques, early recognition of AECOPD, written AECOPD action plan and implementation (when appropriate), promoting physical activity and/or exercise, and other healthy habits including diet and smoking cessation.

**Inhaled Maintenance/Preventative Pharmacotherapies** are long-acting muscarinic antagonists (LAMA) and/or long-acting β₂-agonists (LABA) with or without inhaled corticosteroids (ICS). ICS monotherapy should NOT be used in COPD management.

*Other pharmacotherapies include oral therapies (prophylactic macrolide, and PDE-4 inhibitor, mucolytic agents for patients with chronic bronchitis), alpha-1-antitrypsin augmentation therapy for documented severe A1AT deficiency, and opioids for severe refractory dyspnea (see prior CTS Guideline).*

*Surgical therapies may include lung transplantation and lung volume reduction (including with endoscopic valves).*

**Abbreviations.** A1AT, alpha-1 antitrypsin; AECOPD, acute exacerbation of COPD; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; CTS, Canadian Thoracic Society; mMRC, modified Medical Research Council; prn, as-needed; NIV, noninvasive ventilation.

Essential COPD management goals include improving lung function, reducing dyspnea and other symptoms, enhancing health status, and reducing acute exacerbations of COPD (AECOPD), which are strongly associated with increased mortality.

The approach outlined in Figure 1 should NOT be viewed as a “stepwise” approach, but rather an expanding menu of effective therapies addressing increasing impairment and disability, risk of adverse clinical outcomes, and providing significant clinical benefits.

**Methodology**
This guideline was developed in accordance with the CTS guideline development process, including the GRADE methodology and use of the AGREE II checklist throughout the guideline process.

**Guideline panel composition**
The COPD guideline panel comprised 16 experts: 13 respirologists with experience in COPD management, research and research methodology; 1 primary care physician; 1 pharmacist, knowledge mobilization expert and 1 methodologist.
All author conflicts of interests are available at www.cts-sct.ca/guideline-library/. There were no patients participating in the guideline panel although “patient value COPD outcomes” were also substantiated from the published literature (see the following section).

**Key clinical questions**

The key clinical questions were developed using the Patients/population (P), Intervention(s) (I), Comparison/comparator (C), and Outcome (O)—the PICO model. Three PICO questions were included in this guideline. PICO 1 and 2 were based on the previously published CTS Position Statement on Pharmacotherapy in Patients with Stable COPD – An Update, 2017 and CTS Clinical Practice Guideline on Pharmacotherapy in Individuals with COPD – 2019 Update of Evidence. Stable COPD excludes patients with acute worsening of dyspnea or acute exacerbations. We used evidence/studies from our previous published guidelines and incorporated newly identified evidence after their search date limits. PICO 3 was added in light of new evidence surrounding the impact of inhaled maintenance agents on mortality in COPD. It evaluated the role of pharmacotherapeutic agents compared to other agents in preventing mortality in individuals with COPD. After development of these PICOes and before evidence review, the clinical importance of the outcomes of each PICO was rated by experts, on a graded scale of 1–9, 1 being low and 9 as high defined in theGRADEpro workbook. Scores were ascribed based on perceived patient and clinical relevance. The rating of the outcomes as 7–9 was considered “critical,” 4-6 as “important” and 1-3 as “limited importance.” The outcomes considered for this guideline were primarily (1) dyspnea, health status and exercise tolerance; (2) exacerbations; and (3) mortality (score 7-9); other outcomes included were physical activity, lung function and adverse events (score 4-6). “Patient value COPD outcomes” were also assessed based on a recent systematic review on how patients value COPD outcomes. This study showed that exacerbation and hospitalization are the outcomes that COPD patients rate as most important. Patients rated adverse events as important but on average, less so than symptom relief. Furthermore, this quantitative evaluation was complemented by a recent qualitative study that reported that patients and carers considered that COPD associated breathlessness took over their lives, and saw their worlds shrink physically and socially due to chronic breathlessness.

**Literature search and screening of abstracts**

In addition to the studies included in our previous guidelines, a comprehensive search of literature was performed from MEDLINE, EMBASE and COCHRANE libraries from the end date of the 2019 guideline search (October 18, 2018...
to June 9, 2022) for PICO 1 and 2, and from 1974 to June 9, 2022 for PICO 3. Relevant studies and review articles were hand-searched to identify further articles. See Online Supplement 3 for details of the search strategy, additional studies identified, and the study selection process (pre-defined criteria, titles and abstracts, full text screening). The PRISMA Diagram (Figure 2) presents the records identified, included and excluded, and reasons for exclusion.

### Study design and risk of bias

We included only randomized controlled trials (RCTs) for this guideline. The risk of bias of these RCTs was assessed by (JW/JM) and verified by the methodologist using Cochrane Risk of Bias Tool for RCTs. This tool assessed various components of the RCTs, such as risk of selection bias (randomization, allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data) and reporting bias (selective reporting). See Online Supplement 3 for more details.

### Meta-analysis

Meta-analysis of each outcome was performed if more than one study reported an outcome (Online Supplement 2). This was performed by AL using the Review Manager (RevMan, version 5.4) Cochrane Collaboration software. The risk ratios (RRs), rate ratio, mean difference (MD) and their 95% confidence intervals (CIs) were calculated. A random effects model was used for meta-analysis of all the outcomes. The F statistics and p values of Q statistics were determined to assess heterogeneity among the studies. A p value of the Q statistic ≤ 0.05 was considered to indicate statistically significant heterogeneity. Heterogeneity was classified as moderate ($F \geq 50-74\%$), substantial ($F \geq 30-49\%$) or considerable ($F \geq 25\%$). Where appropriate, subgroup meta-analyses based on timing of measurement of outcomes were performed.

The forest plots list intervention and comparator data in columns 2 and 3. The vertical line of “no effect” indicates no difference in effect of an intervention over control and has a value of 0 for continuous variables and 1 for binary variables. For outcomes such as transitional dyspnea index (TDI) and FEV1, when the diamond of effect size lies on the right side of the line of no effect, there is improvement in these outcomes with intervention compared to control, favoring intervention. On the other hand, for outcomes such as St George’s Respiratory Questionnaire (SGRQ), exacerbations, mortality and adverse events (eg, pneumonia), when the diamond of effect size lies on the left side of the line of no effect, there is a reduction in these scores/events with intervention compared to control, favoring intervention (see Online Supplement 2 for details).

### GRADE

Grading of the quality of the evidence was performed by the Methodologist using the GRADE process. Components considered when evaluating the certainty of an outcome included study design, risk of bias, indirectness of evidence, inconsistency of results, imprecision and other factors such as publication bias, magnitude of effect, confounding and dose-response gradient. See Online Supplement 3 and GRADEpro handbook for additional details on the GRADE methodology.

### Synthesis of evidence-base and clinical judgment of risk-versus-benefit

For each PICO question, we considered the overall certainty of evidence for the critical outcomes. In addition to the quality of the evidence, for each therapeutic approach, the panel considered: the balance between the potential health benefits and harms to individual patients and the overall COPD population; the perceived importance of each outcome to patients; and the burden placed on the patient (these considerations are part of the “Contextualization and Deliberations” domain of guidelines and are explicated in “Clinical Remarks” attached to recommendation, where appropriate). During panel discussions, members also considered resource use, feasibility and acceptability to all stakeholders. The strength of each recommendation (strong or weak) was determined according to the aforementioned factors. To enable this, the evidence (summary of findings tables, forest plots, quality of evidence assessments) was presented to the entire guideline panel. In the situation where there was lack of data, the panel indicated and employed expert consensus opinion.

### Recommendations and classification

The final summary of findings tables, quality of evidence assessments, and corresponding strength for each recommendation (for each PICO question) were discussed by the whole group. Following open and extensive discussions, the entire panel proposed wording and/or updates to prior recommendations, and where applicable, any required change to the strength of the recommendation. They based the strength of each recommendation on the GRADE quality of evidence and synthesis of clinical judgment. The CTS Canadian Respiratory Guidelines Committee (CRGC) executive then vetted the recommendations to optimize language with a view to improving likelihood of uptake. Recommendations were then voted upon using a six-point voting scale, whereby it was defined a priori that a recommendation would only be accepted if each panel member voted for option 1, 2 or 3 (“wholeheartedly agree,” “agree” or “can support”). For a recommendation to be accepted, it had to be voted on by 75% of the eligible panel members and achieve ratings 1, 2 or 3 by 80% of the voting panelists. In the event of a failure to reach 80% of votes with ratings 1, 2 or 3, another period of discussion ensued, whereby dissenting opinions were heard and considered. The recommendation was revised as necessary and followed by a second round of voting using a three-point scale, for which acceptance of a recommendation required a majority (80%)
of panelists to choose option 1 or 2. Throughout this process all recommendations achieved acceptance. We also included practical clinical advice within “Clinical Remarks” attached to recommendations. This advice represents the consensus opinion of panel members based on their expertise.

**Review and approval process**

The CTS independently invited formal review of this guideline by five external (non-CTS) content experts (Canada, Japan, Spain and United States) and two internal (CTS) members. The lead author responded to the comments and made corresponding changes. The Chair and Vice-Chair of the CRGC then completed their own review and provided further feedback for consideration. Upon acceptance, the CRGC recommended approval of the guideline to the CTS Executive Committee for final approval.

**Living guideline/future updates**

The guideline will be reviewed annually to determine the need for and nature of any updates, in accordance with the CTS Living Guideline Model.

**2023 Summary of evidence-based recommendations**

Tables 1-3 present the recommendations for optimal pharmacotherapy and Figure 3 represents a practical clinical treatment pathway for stable COPD. The following recommendations reflect the strength and quality of evidence and high importance to patients and clinicians as key treatment goals. The “evidence based” recommendations of the CTS guideline help inform treatment decision-making, with reference to similar population of patients that were included in these clinical trials, and population-level health risks included our meta-analysis. Note that not all trials of these interventions characterized study populations’ disease severity by CAT, mMRC score and lung function exactly as we have below, but the panel believes that this description closely matches the cohorts represented in corresponding studies.

**Summary PICO 1: Alleviating symptom burden (e.g., dyspnea and exercise intolerance, improving health status)**

For PICO 1, Table 1 lists all the recommendations, their strength and certainty based on the evidence from meta-analysis (summary in Online Supplement Table 1), along with clinical remarks (where applicable). This section presents the optimal use of inhaled and oral pharmacologic maintenance therapies shown to alleviate dyspnea, and to improve exercise tolerance and health status in individuals with stable COPD. Note that this document is not intended to guide the treatment of acute dyspnea.

**Clinical remarks**

Symptom burden of COPD, notably dyspnea and exercise intolerance, negatively affect patient health status. Reduced health status is thought to be related to COPD symptoms and functional impairments. Although symptoms and health status worsen due to acute exacerbations, the relationship between symptom burden and health status has been demonstrated to be independent from confounding variables, which importantly included patients’ exacerbation history. Symptoms are also known to be heterogeneous among patients and across disease severity. It has been shown that patients receiving bronchodilator therapy still have a high symptom burden that negatively affect their health status and sleep, and a substantial proportion of individuals with a high symptom burden may not be receiving optimal bronchodilation. Thus, along with exacerbation risk assessment, monitoring COPD symptom burden consistently and tailoring treatment accordingly should be given more attention, aiming to optimize symptom control and ensure improved health status.

**Patient values and preferences**

We placed high value on alleviating dyspnea and improving health status as treatment goals.

**Review of evidence by outcomes**

**Dyspnea.** Dyspnea is the most common and disabling symptom reported by individuals living with COPD, negatively affecting their performance of activities of daily living. Increasing dyspnea severity is also associated with a greater negative psychological impact. Alleviating dyspnea is a key treatment goal of COPD management. Whereas the modified MRC (mMRC) dyspnea scale is simple-to-use and a validated tool for categorizing disability related to dyspnea and COPD disease severity, it is unresponsive to change. However, other instruments such as the transitional dyspnea index (TDI) have been demonstrated in RCTs to be responsive to both pharmacological and nonpharmacological interventions.

**Recommendations and changes from last CTS COPD Guideline in 2019 with respect to dyspnea** (Table 1): There is change to the recommendation from the last CTS COPD guideline in 2019 that for individuals with low symptom burden and health status impairment (mMRC 1), and only mildly impaired lung function (FEV₁ ≥ 80% predicted), treatment is recommended starting with an inhaled long-acting bronchodilator (LABD) (rather than a short-acting bronchodilator (SABD)), with no significant difference between inhaled LAMA or LABA monotherapy (rec. PICO P.1.A.). In individuals with moderate to high symptoms (mMRC ≥2) and impaired lung function (FEV₁ < 80% predicted), based on updated evidence, there is a change from 2019 with a strong recommendation, with LAMA/LABA dual therapy now being recommended as initial maintenance therapy (rec. PICO P.1.B.). This revised recommendation is based on several RCTs and meta-analyses consistently showing superior efficacy of dual versus monobronchodilator therapy with a similar safety profile. Based on a single study, there is no difference in dyspnea...
Table 1. 2023 recommendations for PICO 1
How does a clinician choose appropriate maintenance pharmacotherapies in individuals with stable COPD to reduce symptom burden, for example, dyspnea and exercise intolerance, and improve health status?

<table>
<thead>
<tr>
<th>2023 Recommendations to reduce symptom burden and improve health status</th>
<th>Strength of recommendation</th>
<th>Certainty of evidence</th>
<th>Evidence from meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P.1.A. In individuals with stable COPD, at low risk of exacerbations§, with low symptom burden and health status impairment (CAT &lt;10, mMRC 1), and only mildly impaired lung function (FEV1 ≥ 80% predicted), we recommend starting initial monotherapy with either LAMA or LABA.</strong></td>
<td>Strong</td>
<td>Moderate to high certainty of greater improvements in dyspnea, exercise tolerance, and health status with LAMA or LABA compared to placebo.</td>
<td>1.1 a, b</td>
</tr>
<tr>
<td>Clinical remark: All studies have characterized individuals with spirometry-based COPD although not all have classified disease severity by FEV1, mMRC and/or CAT exactly as we have in order to compare either LAMA or LABA monotherapy to placebo; however, the panel valued the importance of providing a precise consensus working definition of COPD with mild symptom burden for recommending regular long-acting bronchodilator therapy.</td>
<td>Low certainty of greater improvements in dyspnea, exercise tolerance, and health status with LAMA monotherapy compared to LABA monotherapy.</td>
<td>1.1 c</td>
<td>Table 1; Figures: 1-13; Pages 5-23.</td>
</tr>
<tr>
<td>Note that improvement in exercise capacity may not lead to improvement in physical activity without adding a behavioral intervention.</td>
<td>Low certainty of greater improvement in physical activity with LAMA or LABA compared to placebo.</td>
<td>1.1 d</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>P.1.B. In individuals with stable COPD, at low risk of exacerbations§, with a moderate to high symptom burden/health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV1 &lt; 80% predicted), we recommend starting LAMA/LABA dual therapy as initial maintenance therapy.</strong></td>
<td>Strong</td>
<td>Moderate to high certainty of greater improvements in dyspnea, exercise intolerance, and health status with LAMA/LABA compared to LAMA monotherapy.</td>
<td>1.2 a</td>
</tr>
<tr>
<td>Clinical remark: This recommendation reflects the strength and quality of evidence and high importance to patients and clinicians of alleviating dyspnea and improving health status as key treatment goals of COPD, particularly in individuals with moderate to high symptom burden/health status impairment. Note that improvement in exercise capacity may not lead to improvement in physical activity without adding a behavioral intervention.</td>
<td>Moderate certainty of greater improvements in dyspnea, exercise intolerance, and health status with LAMA/LABA compared to LABA monotherapy.</td>
<td>1.2 b</td>
<td>Table 3; Figures: 24-34; Pages 41-50.</td>
</tr>
<tr>
<td>LAMA/LABA dual therapy is preferred to ICS/LABA combination therapy due to significant improvement in lung function and lower rates of pneumonia. However, ICS/LABA combination therapy is preferred to LAMA/LABA dual therapy in individuals who have COPD with comitant asthma.</td>
<td>Low certainty of greater improvement in physical activity with LAMA/LABA compared to placebo.</td>
<td>1.3</td>
<td>Table 18; Page 129.</td>
</tr>
<tr>
<td><strong>P.1.C. In individuals with stable COPD, at low risk of exacerbations§, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV1 &lt; 80% predicted) despite LAMA/LABA dual therapy or ICS/LABA combination therapy, we recommend step-up to a LAMA/LABA/ICS triple combination therapy.</strong></td>
<td>Strong</td>
<td>Moderate certainty of greater improvements in dyspnea and health status with LAMA/LABA/ICS compared to LAMA/LABA dual therapy or ICS/LABA combination therapy.</td>
<td>1.6 a, b</td>
</tr>
<tr>
<td>Clinical remark: The best option to alleviate dyspnea and other symptoms as well as to improve health status is to combine optimal pharmacotherapy with pulmonary rehabilitation.</td>
<td>Low certainty of greater improvements in dyspnea, exercise intolerance, and health status with LAMA/LABA/ICS combination therapy.</td>
<td>1.5</td>
<td>Table 4; Figures: 35-46; Pages 51-62.</td>
</tr>
</tbody>
</table>

(Continued)
Table 1. (Continued)

<table>
<thead>
<tr>
<th>2023 Recommendations to reduce symptom burden and improve health status</th>
<th>Strength of recommendation</th>
<th>Certainty of evidence</th>
<th>Evidence from meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P.1.D.</strong> In individuals with stable COPD, at low risk of exacerbations, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted) despite LAMA/LABA/ICS triple combination therapy, we suggest not stepping down to LAMA/LABA dual therapy.</td>
<td>Weak</td>
<td>Low to moderate certainty of lack of harm from step down from LAMA/LABA/ICS to LAMA/LABA dual therapy.</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Clinical Remark:</strong> This recommendation reflects the high importance that both patients and clinicians ascribe to alleviating dyspnea and improving health status, particularly in individuals with moderate to high symptom burden/health status impairment. Withdrawing ICS may result in worsening of health status and lung function in some patients. Therefore, we prioritized these outcomes over the risk of adverse events including pneumonia with use of LAMA/LABA/ICS triple combination therapy. However, stepping down may be considered in patients in whom the step up did not result in improved symptoms or health status or because of adverse effects that are of significant importance. No studies of step-down have assessed the impact on dyspnea.</td>
<td>Weak</td>
<td>Insufficient evidence.</td>
<td></td>
</tr>
<tr>
<td><strong>P.1.E.</strong> In individuals with stable COPD, at low risk of exacerbations, currently on LAMA monotherapy, LABA monotherapy or LAMA/LABA dual therapy, we do not suggest adding any of the following oral medications: - Phosphodiesterase-4-inhibitors - Mucolytics - Statins - Anabolic steroids - Oral Chinese herbal medicines - Theophylline</td>
<td>Weak</td>
<td>Low certainty of no improvements in dyspnea, exercise tolerance, physical activity levels, and/or health status with oral therapies compared to placebo.</td>
<td>1.8</td>
</tr>
<tr>
<td><strong>Clinical Remark:</strong> There are limited studies assessing theophylline, which showed equivocal changes in health status. Although there is evidence of a modest improvement in FEV₁ with theophylline, the panel placed greater weight on the risk of adverse events and drug interactions.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>P.1.F.</strong> In all individuals with stable COPD and at a low risk of exacerbations, we recommend against treatment with ICS monotherapy.</td>
<td>Strong</td>
<td>Low certainty of no improvements in dyspnea, exercise tolerance, physical activity levels, and/or health status with ICS monotherapy compared to placebo.</td>
<td>1.9</td>
</tr>
<tr>
<td><strong>Clinical Remark:</strong> When indicated in patients with COPD, ICS should only be administered as part of combination therapy (see above). The panel placed greater weight on the increased risk of adverse events (e.g., pneumonia).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations. CAT, COPD assessment test; mMRC, Modified Medical Research Council; FEV₁, Forced expiratory volume in the first second; AECOPD, Acute exacerbation of COPD; ED, emergency department; LAMA, Long-acting muscarinic antagonist; LABA, Long-acting β₂-agonist; ICS, Inhaled corticosteroid; P1, Patients/population (P); Intervention(s) (I); Comparison/comparator (C); and Outcome (O), (PICO).
### Table 2. 2023 Recommendations for PICO 2

How does a clinician choose appropriate maintenance pharmacotherapies in individuals with stable COPD to reduce the risk of AECOPD?

<table>
<thead>
<tr>
<th>2023 Recommendations to reduce the risk of acute exacerbations</th>
<th>Strength of recommendation</th>
<th>Certainty of evidence</th>
<th>Evidence from meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.2.A. In individuals with stable COPD, at low risk of exacerbations*, a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted), we recommend starting LAMA/LABA dual therapy as initial maintenance therapy.</td>
<td>Strong</td>
<td>Moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA dual therapy compared to LAMA monotherapy.</td>
<td>Supplement Table 1</td>
</tr>
<tr>
<td>Clinical Remark: LAMA/LABA dual therapy is preferred to ICS/LABA combination therapy due to significant improvement in lung function and lower rates of pneumonia. However, ICS/LABA combination therapy is preferred to LAMA/LABA dual therapy in individuals who have COPD with concomitant asthma.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA dual therapy compared to LABA monotherapy.</td>
<td></td>
</tr>
<tr>
<td>P.2.B. In individuals with stable COPD, at high risk of exacerbations*, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted), we recommend the use of LAMA/LABA/ICS triple combination therapy.</td>
<td>Strong</td>
<td>Low to moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA dual therapy compared to ICS/LABA combination therapy.</td>
<td></td>
</tr>
<tr>
<td>Clinical Remark: The panel placed high value on the reduction of exacerbations and mortality as demonstrated in several studies when LAMA/LABA/ICS triple combination therapy was used in this high-risk population compared to LAMA/LABA dual therapy or ICS/LABA combination therapy.</td>
<td></td>
<td>Moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA/ICS triple combination therapy compared to LAMA monotherapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA/ICS triple combination therapy compared to ICS/LABA combination therapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate certainty of greater reduction in rate of exacerbation with LAMA/LABA/ICS triple combination therapy compared to LABA monotherapy.</td>
<td></td>
</tr>
<tr>
<td>P.2.C. In individuals with stable COPD, at a high risk of exacerbations*, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted), we do not suggest step down from LAMA/LABA/ICS triple combination therapy to LAMA/LABA dual therapy.</td>
<td>Weak</td>
<td>Low certainty of benefit of stepdown from LAMA/LABA/ICS to LAMA/LABA</td>
<td></td>
</tr>
<tr>
<td>Clinical Remark: Withdrawing ICS may lower health status and lung function. Withdrawing ICS may also be associated with an increased risk of moderate-severe AECOPD, especially in patients with blood eosinophils counts ≥300 cells/µL.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.2.D. In individuals with stable COPD, at a high risk of exacerbations*, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted) who continue to exacerbate (either moderate or severe) despite being on LAMA/LABA/ICS triple combination therapy, we recommend the addition of macrolide maintenance therapy.</td>
<td>Strong</td>
<td>Moderate certainty of greater reduction in rate of exacerbation with addition of oral macrolide to LAMA/LABA/ICS</td>
<td></td>
</tr>
<tr>
<td>Clinical Remark: the benefits of macrolide maintenance therapy studied over one year should be weighed against the risks of microbial resistance, hearing impairment and cardiac arrhythmia related to QT prolongation/drug interactions.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.2.E. In individuals with stable COPD, with a Chronic Bronchitic Phenotype at a high risk of exacerbations*, with a moderate to high symptom burden and/or health status impairment (CAT ≥10, mMRC ≥2) and impaired lung function (FEV₁ &lt; 80% predicted) who continue to exacerbate despite being on LAMA/LABA/ICS triple combination therapy, we suggest the addition of either Roflumilast or N-Acetylcysteine.</td>
<td>Weak</td>
<td>Low certainty of greater reduction in rate of exacerbation with the addition of Roflumilast compared to placebo?</td>
<td></td>
</tr>
<tr>
<td>Clinical Remark: Moderate certainty of the addition of N-Acetylcysteine.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Abbreviations. CAT, COPD assessment test; mMRC, Modified Medical Research Council; FEV₁, Forced expiratory volume in the first second; AECOPD, acute exacerbation of COPD; ED, emergency department; LAMA, long-acting muscarinic antagonist; LABA, long-acting β₂-agonist; ICS, inhaled corticosteroid; P2, Patients/population (P); Intervention(s) (I); Comparison/comparator (C); and Outcome (O) (PICO). 2.  

*Patients are considered at “Low Risk of AECOPD” if ≤1 moderate AECOPD in the last year (moderate AECOPD is an event with prescribed antibiotic and/or oral corticosteroids) and did not require hospital admission/ Emergency Department visit.  

*Patients are considered at “High Risk of AECOPD” if ≥2 moderate AECOPD or ≥1 severe AECOPD in the last year (severe AECOPD is an event requiring hospitalization or ED visit).
response to treatment between ICS/LABA combination therapy and LAMA monotherapy between 6 and 24 months, and from a number of studies there is no significant difference in dyspnea response to treatment between ICS/LABA combination therapy and either LABA monotherapy or LAMA/LABA dual therapy; however, ICS/LABA combination therapy was associated with higher rates of adverse effects (e.g., pneumonia). Two large studies, The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and The Informing the Pathway of COPD Treatment (IMPACT), performed in symptomatic individuals with COPD at a high risk of future exacerbations, have provided strong evidence for an improvement in dyspnea with LAMA/LABA/ICS triple combination therapy compared to either LAMA/LABA dual therapy or ICS/LABA combination therapy, leading to strong recommendations, accordingly (rec. PICO P.1.C.). Of note, we extrapolated this to a population at low risk of exacerbations but with likely a similar symptom burden.

**Health status.** Health status is often impaired in individuals with COPD and relates to impaired lung function, high psychological and physical symptom burden, low physical activity levels, frequent exacerbations and comorbidities. Health status may be improved in COPD through both pharmacological and nonpharmacological (e.g., pulmonary rehabilitation) interventions. A simple, validated tool such as CAT can be used clinically to routinely assess health status; whereas, other reliable and validated disease-specific health status questionnaires (e.g., St. George’s Respiratory Questionnaire) are frequently used in RCTs.

**Recommendations and changes from last CTS COPD Guideline in 2019 with respect to health status (Table 1):** There is change to the recommendation from the last CTS COPD guideline in 2019 that individuals with low symptom burden and health status impairment (CAT < 10), and only mildly impaired lung function (FEV₁ ≥ 80% predicted), treatment is recommended to start with an inhaled long-acting bronchodilator (LABD) (rather than a short-acting bronchodilator [SABD]), with no significant difference between inhaled LAMA or LABA monotherapy (rec. PICO P.1.A.). In individuals with moderate high symptoms (mMRC ≥ 2, CAT ≥ 10) and impaired lung function (FEV₁ < 80% predicted, based on updated evidence, there is a change from 2019 with a strong recommendation, with LAMA/LABA dual therapy now being recommended as initial maintenance therapy (rec. PICO P.1.B.). Although there was no significant difference in health status seen in RCTs comparing LAMA/LABA dual therapy and ICS/LABA combination therapy, LAMA/LABA dual therapy is preferred due to greater improvements in lung function and lower rates of pneumonia, unless a patient has been diagnosed with concomitant asthma. We also extrapolated data from two large studies performed in symptomatic individuals with COPD at high risk of future exacerbations, which add to previous evidence of a significant improvement in health status (whether looking at mean change from baseline or a responder analysis) with
LAMA/LABA/ICS triple combination therapy compared to either LAMA/LABA dual therapy or ICS/LABA combination therapy, leading to a strong recommendation (rec. PICO P.1.C.)

Other recommendations with respect to dyspnea and health status (Table 1): In individuals with moderate to high health status impairment (CAT ≥ 10) and/or FEV₁ < 80% predicted, based on updated evidence, there is a change from 2019, with a weak recommendation to continue LAMA/LABA/ICS triple combination therapy rather than stepping down to LAMA/LABA dual therapy (rec. PICO P.1.D.). Withdrawing ICS may result in worsening of health status and lung function. Stepping down may be considered in patients when there are concerns that the step-up may not have been justified in the first place or because of adverse effects. No studies of step-down have assessed the impact on dyspnea. Based on evidence, we do not suggest adding any of the oral medications to improve dyspnea, exercise tolerance, physical activity levels and/or health status (rec. PICO P.1.E.). Additionally, in all individuals with stable COPD and a low risk of exacerbations, we recommend against treatment with ICS monotherapy (rec. PICO P.1.F.).

Exercise tolerance and physical activity
Physical activity (PA) is any bodily movement that results in energy expenditure above the resting state and is associated with reduced health resource use and all-cause mortality in COPD; whereas exercise is a planned, structured, repetitive sub-set of PA. Regular physical activity reduces hospital admission and mortality in COPD according to a population-based cohort study. PA can be assessed with questionnaires or objectively through validated wearable devices (eg, step counter, accelerometer). Exercise tolerance can be assessed using field tests (eg, 6-min walk test, shuttle walk test) or laboratory tests (eg, cardiopulmonary exercise test). In patients with COPD, symptoms including dyspnea as well as limb (peripheral muscle) fatigue and discomfort limit exercise tolerance can improve with both pharmacological (eg, LABD) and nonpharmacological interventions (eg, pulmonary rehabilitation). However, improvements in exercise tolerance may not result in maintained improvement in PA without a behavioral intervention.

No new evidence assessing the impact of maintenance pharmacotherapy on exercise tolerance or physical activity in COPD was available since the last CTS update in 2019; therefore, there were no changes to recommendations from the last update specifically in relation to these two outcome measures.

PICO 2: Preventing AECOPD
For PICO 2, Table 2 lists all the recommendations, their strength and certainty based on the evidence from meta-analysis (summary in Online Supplement Table 1), along with clinical remarks (where applicable). This section discusses the optimal use of inhaled and oral pharmacologic maintenance therapies shown to prevent AECOPD in individuals with stable COPD. Note that this document is not intended to guide the treatment of acute exacerbations.

Clinical remarks
In Canada, AECOPD is the most frequent cause of acute hospitalization in adults related to chronic conditions. From a patient perspective, AECOPD contributes to a decline in lung function, poor health status and increased susceptibility to repeated exacerbations. This results in increased morbidity and mortality associated with COPD. And COPD accounts for more than 80% of total deaths from chronic respiratory disease globally. A primary goal of the outpatient management of COPD is to prevent future AECOPD. A treatment approach that is proactive and prevents future AECOPD will improve health status, reduce healthcare utilization and reduce mortality.

Patient values and preferences
We placed high value on the prevention of AECOPD as a treatment goal. Given the significance that AECOPD has on an individual (both short- and long-term outcomes) and the healthcare system, a pro-active approach to reduce exacerbation is necessary.

Review of evidence by outcomes
Moderate to severe exacerbations. COPD exacerbation is either symptom-based requiring a change of at least one major symptom (dyspnea, sputum purulence, sputum volume), or event-based requiring a change of at least one major symptom and use of antibiotics and/or systemic corticosteroids (moderate exacerbation) or event based requiring a change of hospital admission (severe exacerbation). The best way of identifying subjects susceptible to exacerbations is through their exacerbation history, where frequent exacerbations predict risk of future events. Exacerbations of COPD have profound impact on patients’ health status, functional capacity and lung function. The frequency and severity of exacerbations varies, and high risk exacerbations which has been used as operational definition in many large clinical trials has been defined as either frequent moderate exacerbations (exacerbations requiring antibiotic and/or prednisone treatment) or severe exacerbations (resulting in emergency department or hospital admission). Severe exacerbations have a poor prognosis with increased mortality, significantly impaired health status and increased risk of further exacerbations. Patients who have been admitted to hospital for a severe exacerbation of COPD are at substantial risk of rehospitalization. Therefore, targeted interventions aimed at preventing or reducing the frequency and severity of exacerbations should be a priority for improving patients’ prognoses.

Recommendations and changes from last CTS COPD Guideline in 2019 with respect to moderate to severe exacerbations (Table 2): In stable individuals at a low risk of exacerbations and with moderate to high symptom burden, health status impairment (mMRC ≥ 2, CAT ≥ 10) and
FEV\textsubscript{1} < 80% predicted, based on updated evidence, there is a change from 2019, with a recommendation to start LAMA/LABA dual therapy as initial maintenance therapy (rec. PICO P.2.A.). This aligns with the recommendation P.1.B made in PICO 1. Furthermore, LAMA/LABA dual therapy is preferred to ICS/LABA combination therapy due to significant improvement in lung function and lower rates of adverse effects (eg, pneumonia). However, ICS/LABA combination therapy is preferred to LAMA/LABA dual therapy in individuals with both COPD and concomitant asthma.

Additionally, in stable individuals with COPD at a high risk of exacerbations, with a high symptom burden, health status impairment (mMRC ≥ 2, CAT ≥ 10) and FEV\textsubscript{1} < 80% predicted, based on updated evidence as previously described, there is a change from 2019, with a strong recommendation to start LAMA/LABA/ICS triple combination therapy as initial maintenance therapy (rec. PICO P.2.B.). For symptomatic individuals with impaired health status meeting the definition of having a high AECOPD risk (see Figure 3), two large RCTs, IMPACT\textsuperscript{42} and ETHOS\textsuperscript{41} demonstrated the benefits of triple inhaled LAMA/LABA/ICS (administered in a single inhaler) versus dual inhaled LAMA/LABA or ICS/LABA. In IMPACT, LAMA/LABA/ICS triple combination therapy was associated with a significantly lower annual rate of moderate or severe exacerbations during treatment than ICS/LABA combination therapy or LAMA/LABA dual therapy (0.91 vs 1.07 vs 1.21 exacerbations/year, respectively). LAMA/LABA/ICS triple combination therapy was also associated with a significantly lower risk of severe exacerbations compared to LAMA/LABA dual therapy (0.13 vs 0.19 severe exacerbations/year; rate ratio 0.66, 95%CI 0.56-0.78). In the ETHOS trial, the annual rate of moderate or severe exacerbations was 24% lower with 320 µg budesonide LAMA/LABA/ICS triple combination therapy compared with LAMA/LABA dual therapy, and 13% lower compared to ICS/LABA combination therapy. Similarly, the annual rate of moderate or severe exacerbation was significantly lower with 160 µg budesonide LAMA/LABA/ICS triple combination therapy compared with LAMA/LABA dual therapy and ICS/LABA combination therapy. No difference in annual rate of moderate or severe exacerbation (or time to first moderate or severe exacerbation) was observed between LAMA/LABA/ICS groups with differing ICS doses (rate ratio 1.00; 95%CI, 0.91-1.10).

Step down from LAMA/LABA/ICS triple combination therapy to dual combination therapies is not suggested (rec. PICO P.2.C.) for individuals at high risk of exacerbations. Withdrawing ICS, in addition to the possibility of lowering health status and lung function, can be associated with an increased risk of moderate-severe AECOPD; this could be more harmful in individuals with blood eosinophils counts ≥300 cells/µL. In COPD symptomatic individuals with impaired health status, at high risk of AECOPD, who continue to exacerbate despite being on LAMA/LABA/ICS triple combination therapy, we recommend the addition of macrolide maintenance therapy in appropriate patients who have normal QT interval on electrocardiograms (ECGs), no significant drug interactions with concomitant medications and no evidence of either indolent or active infection with atypical mycobacteria\textsuperscript{62} (rec. PICO P.2.D).

In individuals with COPD, with a chronic bronchitic phenotype at high risk of exacerbations, with a moderate to high symptom burden and/or health status impairment who continue to exacerbate despite being on LAMA/LABA/ICS triple combination therapy, we suggest the addition of either roflumilast or N-acetylcysteine (rec. PICO P.2.E.). We continue to recommend against the use of theophylline or systemic oral corticosteroids such as prednisone for maintenance treatment in COPD. There is no role for ICS monotherapy and ICS should only be used in combination with inhaled long-acting bronchodilators.\textsuperscript{13} Administering ICS with LAMA/LABA in separate inhalers has not been well studied in COPD, but evidence to date demonstrates incremental benefit with single-inhaler triple therapy compared to multiple-inhaler triple therapy.\textsuperscript{63}

**Other considerations:** When combination ICS/LABA or triple LAMA/LABA/ICS is used, high doses of ICS\textsuperscript{64} are not typically necessary to achieve optimum benefit in COPD, as shown by a relatively flat dose-response curve\textsuperscript{65,66} and greater incidence of adverse effects with higher inhaled ICS doses. In regard to moderate to severe exacerbations, the ETHOS study demonstrated no significant difference in exacerbation reduction between the moderate and low dose ICS, but did demonstrate a mortality benefit\textsuperscript{41} favoring the moderate dose of inhaled ICS triple combination therapy. As noted, the incidence of pneumonia is higher with inhaled ICS-containing maintenance therapy, especially in individuals with severe and very severe disease. However, these are also the individuals who benefit most from ICS-containing regimens. It is also important to acknowledge that there are many other factors associated with increased risk of pneumonia in individuals with COPD.\textsuperscript{67} The clinical significance of increased pneumonia in individuals with COPD who use ICS-containing inhaled maintenance therapy must be balanced against concurrent documented improvements in lung function, health status and a reduction in exacerbations. The number needed to treat (NNT) has been established at 4 patients for 1 year to prevent 1 moderate to severe exacerbation with Triple Therapy versus combined inhaled long-acting dual bronchodilator therapy, and the number needed to harm (NNH) at 33 patients for 1 year to cause 1 pneumonia,\textsuperscript{68} thus highlighting the risk-benefit ratio. We also note that pneumonia has been recognized as a class effect of ICS-containing therapies in individuals with COPD, with no conclusive evidence of intra-class differences.

**PICO 3: Reducing mortality**

For PICO 3, Table 3 lists all the recommendations, their strength and certainty based on the evidence from meta-analysis (summary in Online Supplement Table 1), along with clinical remarks (where applicable). This section presents the optimal use of pharmacologic maintenance therapies shown to reduce mortality in individuals with stable COPD.
**Clinical remarks**

Following a severe exacerbation of COPD, not only does the rate of subsequent exacerbations increase and time between exacerbations decrease, but there is an increased risk of mortality.\(^9\) Mortality among patients discharged from hospital can be as high as 6.1% (5.8% in men and 6.8% in women) within 90 days of admission, 11.1% when mortality combines in-hospital plus a 90 day follow up\(^9\) and an increased risk of death that persists to one year.\(^70\) Moreover, the impact of an exacerbation goes beyond the lungs. An AECOPD also increases the risk of cardiovascular (CV) events, including acute coronary syndrome and stroke in the first 30 days and up to 1 year following the AECOPD.\(^71\) CV events increase quickly, in the first 10 days following a moderate exacerbation,\(^72\) and the risk persists for up to a year.\(^71\) As the third leading cause of death, a critical COPD treatment goal should be to reduce the risk of COPD-related mortality.

**Patient values and preferences**

We placed high value on reducing mortality as a treatment goal.

**Review of evidence by outcome**

**Mortality.** Pharmacologic maintenance therapy comparing monotherapy (LABA, LAMA or ICS) to placebo, dual therapy (LAMA/LABA) to monotherapy (LABA or LAMA), combination therapy (ICS/LABA) to monotherapy (LABA or LAMA) have not shown a reduction in mortality (summary in Online Supplement Table 1). ICS/LABA combination therapy has shown decrease mortality compared to LAMA/LABA dual therapy; these results are mainly derived from two major RCTs, IMPACT and ETHOS.\(^41,42\) Some oral therapies have not shown a reduction in mortality (Vitamin D, roflumilast, mucolytic agents, theophyllines, statins) and for others there is a lack of data (N-acetylcysteine, macrolides) (Table 1).

Two large RCTs, IMPACT and ETHOS, have helped to inform the role of triple inhaled LAMA/LABA/ICS versus dual inhaled LAMA/LABA or ICS/LABA.\(^41,42\) Eligible patients could have a prior diagnosis of asthma, but not current asthma, and the RCTs were enriched for individuals with high symptom burden, impaired health status (score CAT ≥10) and exacerbations in the previous year (≥2 moderate exacerbations and/or ≥1 severe exacerbation requiring hospital admission). ETHOS and IMPACT assessed the risk of all-cause mortality as a prespecified secondary endpoint or other endpoint. In ETHOS, the risk ratio of all-cause mortality for triple inhaled LAMA/LABA/ICS with 320 µg budesonide (but not for 160 ug budesonide), vs LAMA/LABA dual therapy was 0.58 (95%CI, 0.34-0.99), and in IMPACT it was 0.64 (95%CI, 0.42-0.97). In ETHOS, the Hazard Ratio (HR) of all-cause mortality for triple inhaled LAMA/LABA/ICS 320 µg budesonide (but not for 160 ug budesonide) versus LAMA/ LABA was 0.54 (95%CI, 0.34-0.87). Neither IMPACT nor ETHOS, demonstrated a difference when triple inhaled LAMA/LABA/ICS was compared to ICS/LABA combination therapy. In both studies, in a separate analysis, the robustness of the mortality findings was assessed after additional data retrieval for patients missing week 52 vital status in the original analyses.\(^73,74\) Vital status data were reported for over 99% of the intention-to-treat population. For triple inhaled LAMA/ LABA/ICS, all-cause mortality was still statistically reduced versus LAMA/LABA dual therapy. Independent adjudication confirmed lower rates of respiratory and cardiovascular death. Results were similar when the first 30 days of treatment were excluded from the analysis.

**Recommendations with respect to mortality (Table 3):** In individuals at high risk of exacerbations, with a high symptom burden, health status impairment (mMRC ≥ 2, CAT ≥ 10) and FEV\(_1\) < 80% predicted, based on this new evidence, we make a strong recommendation for use of LAMA/LABA/ICS triple combination therapy over LABA/ LAMA dual therapy (rec. PICO P.3.A.) and over ICS/LABA combination therapy (rec. PICO P.3.B.) to reduce mortality. The greater benefit of combination triple therapy over LABA/LAMA dual therapy and ICS/LABA combination therapy is not only of reducing mortality but also for improving dyspnea, health status, lung function and preventing moderate to severe AECOPD in this particular and well-defined population of patients.

**Revision to the COPD pharmacotherapy – Figure 3**

Recommended COPD pharmacotherapy promotes an evidence-informed approach that aligns proven effective treatment with symptom burden, risk of future exacerbations and mortality risk (Figure 3). Since the 2019 CTS Guideline, there has been much clinical research that has informed this current guideline.

An important change since 2019 is the recommendation for use of long-acting inhaled bronchodilator maintenance therapy in all symptomatic individuals with COPD, including those with mild symptom burden, acknowledging that as-needed short-acting bronchodilator therapy should also be utilized by all individuals across the spectrum of COPD severity.

For individuals with moderate and severe disease with a low risk of future AECOPD, single inhaled LAMA/ LABA dual therapy is now indicated given its proven superiority over inhaled LAMA or LABA monotherapy in this setting. In addition, individuals with moderate and severe disease who are at high risk of future AECOPD (definition unchanged from 2019 – ≥2 moderate AECOPD and/or ≥1 severe AECOPD in the past year) should be treated with single inhaled LAMA/LABA/ICS triple combination therapy because of proven superiority and benefits, including most importantly, significant reduction in mortality. Triple inhaled LAMA/LABA/ICS therapy, in a single inhaler triple therapy (SITT), is favored over multiple inhalers, because of potential increased benefits, increased adherence and reduced chance of errors in inhaler technique.\(^65,75,76\)
This comprehensive guideline provides updated pharmacotherapeutic recommendations for COPD, based on newly published literature since the 2019 Guideline Update on Pharmacotherapy in Individuals with Stable COPD. Our PICO-driven questions elicit evidence for the best pharmacological therapy to alleviate symptoms and to improve health status, to reduce exacerbations and its complications such as hospital admissions and to reduce mortality. The novelty of this guideline, it being the first to our knowledge to do this, is to report on the impact of maintenance pharmacotherapies on mortality in COPD. This guideline also proposes a revised and practical treatment pathway based on the recommendations. As per guideline standards, our approach is based on a careful systematic review and meta-analysis (Online Supplementary document), and takes into account the quality of the evidence and the multifaceted balance between the benefits and harms of treatment.

In this new guideline, we place a high value on the alleviation of symptoms, in particular dyspnea, which is the most debilitating symptom in COPD, and improvement of health status as treatment goals (PICO1). Inhaled maintenance therapy with LABD is superior to short-acting bronchodilators in achieving these goals. An important change since 2019 is the recommendation for use of LABD maintenance therapy in all individuals who have persistent symptoms, even mild, with COPD. Also, in individuals with moderate to severe dyspnea, and similarly, in individuals with moderate to severe reduced health status, LAMA/LABA dual therapy is strongly recommended over LAMA or LABA monotherapy. However, we have not recommended prescribing LABD treatment in symptomatic persons who currently or formerly smoked cigarettes but have preserved lung function as assessed by spirometry (ie, patients who do not meet criteria for COPD). Although some have advocated for treatment in these individuals, it has been demonstrated that inhaled LABD therapy does not decrease respiratory symptoms in subjects not proven to have COPD by spirometry.17

---

**Discussion**

This comprehensive guideline provides updated pharmacotherapeutic recommendations for COPD, based on newly published literature since the 2019 Guideline Update on Pharmacotherapy in Individuals with Stable COPD. Our PICO-driven questions elicit evidence for the best pharmacological therapy to alleviate symptoms and to improve health status, to reduce exacerbations and its complications such as hospital admissions and to reduce mortality. The novelty of this guideline, it being the first to our knowledge to do this, is to report on the impact of maintenance pharmacotherapies on mortality in COPD. This guideline also proposes a revised and practical treatment pathway based on the recommendations. As per guideline standards, our approach is based on a careful systematic review and meta-analysis (Online Supplementary document), and takes into account the quality of the evidence and the multifaceted balance between the benefits and harms of treatment.

In this new guideline, we place a high value on the alleviation of symptoms, in particular dyspnea, which is the most debilitating symptom in COPD, and improvement of health status as treatment goals (PICO1). Inhaled maintenance therapy with LABD is superior to short-acting bronchodilators in achieving these goals. An important change since 2019 is the recommendation for use of LABD maintenance therapy in all individuals who have persistent symptoms, even mild, with COPD. Also, in individuals with moderate to severe dyspnea, and similarly, in individuals with moderate to severe reduced health status, LAMA/LABA dual therapy is strongly recommended over LAMA or LABA monotherapy. However, we have not recommended prescribing LABD treatment in symptomatic persons who currently or formerly smoked cigarettes but have preserved lung function as assessed by spirometry (ie, patients who do not meet criteria for COPD). Although some have advocated for treatment in these individuals, it has been demonstrated that inhaled LABD therapy does not decrease respiratory symptoms in subjects not proven to have COPD by spirometry.17

---

**Figure 3. COPD Pharmacotherapy.**

This figure promotes an evidence-informed approach that aligns proven effective treatments with spirometry, symptom burden, risk of future exacerbations and mortality risk. Because of the clinical heterogeneity in COPD, spirometry should not be used in isolation to assess disease severity and this is why it is also important to perform a thorough clinical evaluation of the patient, including symptom burden and risk of exacerbations that permits the implementation of treatments that are specific for subpopulations. SABD prn (as needed) should accompany all recommended therapies across the spectrum of COPD.11

Symptom burden encompasses shortness of breath, activity limitation, and impaired health status.11 Individuals are considered at “Low Risk of AECOPD” if ≤1 moderate AECOPD in the last year (moderate AECOPD is an event with prescribed antibiotic and/or oral corticosteroids) and did not require hospital admission/ED visit. Individuals are considered at “High Risk of AECOPD” if ≥2 moderate AECOPD or ≥1 severe exacerbation in the last year (severe AECOPD is an event requiring hospitalization or ED visit).

**Triple inhaled ICS/LAMA/LABA combination therapy should preferably be administered in a single inhaler triple therapy (SITT), and not in multiple inhalers (see text), although we acknowledge that some patients continue to prefer separate inhalers.** Oral pharmacotherapies in this group include prophylactic macrolide, and PDE-4 inhibitor and mucolytic agents for patients with chronic bronchitis. **Inhaled corticosteroids.**
There are many effective therapies that prevent AECOPD and the choice of therapy should be determined based on the risk of future AECOPD (PICO 2). The goal of preventing AECOPD is to significantly minimize all the negative impacts of AECOPD such as symptom burden, health status worsening, hospital admission and mortality. It is recommended that individuals with moderate and severe disease who are at high risk of AECOPD be treated with SITT because of its many proven benefits, including the reduction of moderate and severe AECOPD and most importantly, significant reduction in mortality.

To date, demonstrating benefits on mortality in RCTs has been difficult, requiring large and selected populations at high risk of death (PICO 3). From an historical perspective, the TORCH and SUMMIT trials, both powered for the primary outcome of all-cause mortality, failed to show a statistically significant benefit on survival for ICS/LABA combination therapy compared with placebo. The inclusion criteria for TORCH were based on prebronchodilator FEV₁ <60% predicted and no requirement for a history of previous exacerbations. The SUMMIT inclusion criteria were based on a history or risk of cardiovascular disease, moderate COPD with a post-bronchodilator FEV₁ of 50–70% predicted (primarily COPD with moderate airflow obstruction or GOLD 2) and no prior history of exacerbations (75% had no exacerbations in the prior year). From IMPACT and ETHOS, it became evident that the TORCH and SUMMIT trials did not include a population at a sufficiently high risk of death from COPD (ie, those with a history of frequent and/or severe AECOPD). These most recent RCTs were enriched for symptomatic patients (CAT ≥ 10) with a history of frequent (≥2 moderate exacerbations) and/or severe exacerbations (≥1 exacerbation requiring a hospital admission). Evidence of reduction in mortality has been strengthened from a postanalysis using the final retrieved database, which included Week 52 vital status for 99.6% of the intent-to-treat population risk of death. Furthermore, adjudicated causes of death suggest a potential role in reducing mortality that may not only be directly by reducing exacerbation but also cardiovascular outcomes. Despite an increased risk of pneumonia with ICS use, the overall clinical benefit of a reduction in mortality outweighed the risk of pneumonia as an adverse event and/or serious adverse event. Furthermore, a meta-analysis of RCTs has demonstrated that mortality from pneumonia was not different with ICS containing regimens compared with non-ICS containing regimens (58/31396 vs 74/22544; relative risk 0.97 (95%CI 0.58-1.60; p=0.89)).

While discussed, the use of biomarkers such as blood eosinophil count have not been reviewed in this guideline, which is based on systematic reviews of RCTs. Recommendations are limited to some clinical remarks since most of the data on blood eosinophil count are derived from observational studies or post-hoc analysis. However, there is consensus from experts that a subgroup of COPD patients at risk of exacerbations with blood eosinophils ≥300 cells/μL have a stronger likelihood of reduced exacerbations when patients are treated with ICS containing regimen or increased exacerbations when ICS is withdrawn.

This guideline has not considered factors that might influence the specific choice of inhaled medication beyond the molecule, side effects, and single-inhaler delivery route. Ensuring proper inhalation technique is one of the most important aspects of COPD care and studies have shown that errors in inhaler handling in this population can lead to increased emergency department (ED) admissions for AECOPD, hospitalizations, systemic corticosteroid requirements and antibiotic use. Also of importance, use of multiple devices with a similar inhalation technique has been shown to be associated with a lower rate of exacerbations and use of rescue medication compared to those who were prescribed multiple devices requiring different techniques.

Combination therapies for most of the studies in this guideline used single inhalers; similar efficacy cannot be extrapolated to achieving the same combinations with multiple-inhaler therapy. In the INTREPID study, a pragmatic RCT, SITT for COPD resulted in significantly more patients demonstrating improvements in health status and lung function compared to corresponding multiple-inhaler triple therapy.

The environmental impact and global warming potential associated with metered dose inhalers (MDIs) have been recognized for decades. Chlorofluorocarbons (CFCs) used originally as propellants in MDI devices were phased out under the Montreal Protocol in 1987 due to their ozone-depleting properties and replaced by two hydrofluoroalkane (HFA) propellants. Unfortunately, HFAs are now recognized as potent greenhouse gases with global warming impact. Not all MDIs have the same carbon footprint; dry-powder inhalers and emerging devices which use novel propellants constitute a lower carbon footprint option. This is particularly relevant for short-acting beta-agonist (SABA) inhalers, which constitute 71% of total inhaler use in Canada. Selection of inhaler device should be a shared provider-patient decision informed by many factors including patient inhaler technique, preference, cost/insurance coverage and clinical course. The environmental impact of otherwise equivalent inhaler options should also be a relevant consideration.

**Comparison to other recent guidelines**

The 2023 CTS Guideline recommendations are consistent to other recent guidelines such as NICE and ATS, and the GOLD report 2023 but based on the meta-analysis the Canadian guidelines are more progressive. It is well recognized in all guidelines that treatment should not only be based on lung function alone but taking into consideration other measures such as symptoms, health status and risk of exacerbations. All the recent guidelines have recognized the superiority of the LAMA/LABA dual therapy versus monotherapy in patients with high symptom burden, poor health status and low risk of future exacerbations. The 2023 CTS Guideline, ATS and GOLD all recommended starting with dual therapy in this patient population. In symptomatic patients with previous history of recurrent moderate or severe exacerbations, all recommended using single inhaler triple therapy (LAMA/LABA/ICS). CTS is more proactive recommending upfront triple therapy for these patients. The GOLD recommendations make the distinction for patients who have blood eosinophil count of <100 cells/μL not to be increased from LABA/LABA dual therapy to triple therapy but to add oral therapies such as azithromycin or N-acetylcysteine; CTS
recommended these oral medications in addition to triple therapy. CTS and GOLD, which rely on the most recent and larger clinical trials, do not recommend withdrawing ICS in patients with moderate-high symptom burden and high risk of exacerbations unless there are adverse effects of importance; it is also not recommended in COPD patients with blood eosinophils counts ≥300 cells/µL. All guidelines mention adverse effects, but prioritization should be given to the benefit of the outcomes over the risk of adverse events including pneumonia. Finally, all the guidelines recommend minimizing the number of inhalers and the number of different types of inhalers used by each patient as far as possible.

Conclusion

In conclusion, we present an evidence-based guideline with updated recommendations focused on 3 outcome areas: symptoms (dyspnea)/health status, exacerbations and mortality. We recommend: LABA maintenance therapy in all symptomatic patients with COPD confirmed by spirometry and single inhaler dual therapy LABD in those with moderate to severe dyspnea and/or poor health status, with a step up to single-inhaler triple therapy in those with persistent moderate to severe dyspnea and/or poor health status despite treatment with single inhaler dual therapy with LAMA/LABA or ICS/LABA. Given that SITT reduces mortality in individuals with moderate-severe disease and a high risk of AECOPD, we also suggest SITT in all patients at high risk of AECOPD. Our findings suggest the need to implement targeted case-finding strategies for patients to benefit from these therapeutic options. This 2023 CTS Guideline on the Pharmacotherapy Management of Stable COPD guides clinicians in implementing an exciting new paradigm in COPD management, wherein the goals of treatment include not only alleviating symptoms and preventing exacerbations, but also reducing mortality.

Acknowledgments

The authors would like to thank the CRGC Executive Members (Samir Gupta and Sanjay Mehta), and the CTS Executive Members (Richard Leigh, Donna Goodridge and Melinda Solomon) for their input and guidance. We would also like to acknowledge with sincere appreciation our expert reviewers who made valuable contributions to the manuscript: Gerard J. Criner, Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA; Miriam Barrecheuguen, Department of Pneumology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain; Jun Ueki, Clinical Research Unit of Respiratory Pathophysiology, Juntendo University Graduate School of Health Care and Nursing, Takasaki, Urayasu City, Japan; Christine Jenkins, Head and professor of respiratory medicine, UNSW, Sydney, Australia; Barry Powers, Editor-in-Chief, Canadian Pharmacists Association, Ottawa, Ontario, Canada; Kevin Bussey, Clinical Editor, Canadian Pharmacists Association, Ottawa, Ontario, Canada; Alan Kaplan, Family Physicians Airways Group of Canada, Richmond Hill, Ontario, Canada; and Roger Goldstein, West Park Healthcare Centre, University of Toronto, Toronto, Ontario, Canada.

Author contributions

JB, MB, PH, DDM executive committee members who led the guideline and systematic review, wrote the manuscript, responded to the reviewers and made the final review; SDA, MFB, SBK, AU, FM, JDM, SM, EP, DS, JW, BLW committee members; AL methodologist; AVD guideline coordinator. Every author contributed in the review evidences from the meta-analysis, committee meetings and recommendations; every author reviewed the manuscript.

Editorial independence

The CTS COPD guideline panel is accountable to the CTS CRGC and the CTS Board of Directors. The CTS COPD guideline panel is functionally and editorially independent from any funding sources of the CTS and does not receive any direct funding from external sources. The CTS receives unrestricted grants that are combined into a central operating account to facilitate the knowledge translation activities of the CTS Assemblies and its guideline panels. No funders played a role in the collection, review, analysis or interpretation of the scientific literature or in any decisions regarding the key messages presented in this document.

Disclosure statement

Members of the CTS COPD Guideline Panel declared potential conflicts of interest at the time of appointment, and these were updated throughout the process in accordance with the CTS Conflict of Interest Disclosure Policy.

J. Bourbeau reports grants from McGill University, the McGill University Health Centre Foundation, the Canadian Institute Health Research, Grifols, Novartis, Sanoﬁ, and the Respiratory Health Network of the Fonds de la recherche en santé du Québec; grants and personal fees from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Trudell Canada Ltd; and personal fees from Pfizer Canada Ltd, and COVIS Pharma Canada Ltd, outside the submitted work.

M. Bhutani reports personal fees and grants outside the submitted work from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Novartis, Sanoﬁ-Genzyme, the Canadian Institute Health Research, CHEST, The Lung Association of Alberta, The University of Alberta Hospital Foundation, Alberta Innovates Health Solutions, Valeo, and Covis.

P. Hernandez reports grants from the Canadian Institute Health Research, the Lung Association of Nova Scotia, the Nova Scotia Health Authority Research Fund, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Janssen, Merck, Novartis, Sanoﬁ-Aventis, and Trudell, outside the submitted work.

S. D. Aaron receives grants from CIHR. He has received speaking fees from Sanofi. He is a consultant for Boehringer Ingelheim and Astra Zeneca.

M-F. Beauchesne reports grants from the Cercle du doyen Faculté de pharmacie, Université de Montréal and Astra Zeneca Canada Ltd.

A. D’Urzo reports receiving research, consulting and lecturing fees from GlaxoSmithKline, Sepracor, Schering Plough, Alanta, Methapharma, AstraZeneca, ONO pharmaceuticals, Merck Canada, Forest Laboratories, Novartis Canada/USA, Boehringer Ingelheim (Canada) Ltd, Pfizer Canada, SkyePharma, and KOS Pharmaceuticals and Almirall, Sanofigenzyme and TEVA Canada, Valeopharma Canada.

F. Malatais reports grants from AstraZeneca and GlaxoSmithKline, Boehringer Ingelheim, GSK, Sanoﬁ, and Novartis, and personal fees for serving on speaker bureaus and consultation panels from GlaxoSmithKline, Grifols, and Novartis. He is financially involved with Oxynov, a company which is developing an oxygen delivery system.

S. Mulpuru reports grants outside the submitted work from Canadian Institute of Health Research and Canadian Lung Association in partnership with Boehringer Ingelheim Canada Ltd and Astra Zeneca Canada Ltd.
References


